XNK Therapeutics appoints Hans Ericson as CFO

May 5, 2020

XNK Therapeutics AB (“XNK”) today announced the appointment of Hans Ericson as Chief Financial Officer

Hans Ericson is a senior finance professional with more than 20 years’ experience in international business and public traded companies. He has had a number of leading positions including at Ericsson and Elekta. Hans has also worked as a consultant in various areas, from start-ups to large research organizations, including Research Institute of Sweden (RISE).

“I am very pleased to have Hans Ericson joining the XNK team,” says Johan Liwing, CEO of XNK Therapeutics. “He brings solid experience to the company that will help us take XNK to the next level.”

For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe and certain other jurisdictions. Additional patent applications have been filed.